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Abstract
The results of studying the status of hemostasis system in pregnant women with fetal loss syndrome and thrombophilia are
demonstrated.
The objective of the research was to study the peculiarities of hemostasis system in pregnant women with fetal loss
syndrome on the background of thrombophilia.
Materials and methods. There were examined 60 pregnant women with fetal loss syndrome and thrombophilia and 30
healthy pregnant women without aggravated anamnesis. All women underwent examination using clinical and laboratory
methods.
Results and discussion. The disorders of the vascular-platelet and coagulation elements of hemostatic process be-
ing characterized by hypercoagulation, reduction in natural anticoagulants, intensification of thrombosis processes were
determined.
Conclusions. In pregnant women with fetal loss syndrome on the background of thrombophilia disorders of the vascular-
thrombocytic and coagulation elements of hemostatic process were observed.
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Problem statement and analysis of the
recent research
The relevant problem of modern obstetrics is the management
of pregnancy in women with fetal loss syndrome. To prevent
miscarriage or premature delivery, special importance is given
to prenatal observation, timely diagnostics and correction of
detected disorders.
According to literature data, 40% of perinatal losses are as-
sociated with the presence of thrombophilia [1, 2]. Pregnancy
is a condition that can be called a certain “examination” for the
presence of hereditary (genetic) or acquired thrombophilia as
it is accompanied by physiological hypercoagulation thereby
contributing to the realization of latent thrombophilia not only
in the form of thromboses and thromboembolia, but also ob-
stetric complications [3].
The probability of fetal loss or the development of placen-
tal insufficiency in women with thrombophilia is very high.
This obstetric pathology may be caused by antiphospholipid
syndrome, hyperhomocysteinemia, hereditary disorders of
hemostasis. The coexistence of these pathological conditions
significantly increases the risk of pregnancy complications
[4].
The status of hemostasis system determines the course and
consequences of pregnancy for both mother and fetus. Lately,
peculiar attention has been given to the study of hemostasis
system indices as an important component in the development
of obstetric complications. Due to the imbalance of procoagu-
lant and anticoagulant mechanisms, thrombophilia may lead
not only to the development of thrombosis during pregnancy
and postnatal period, but also to different placental vascular
complications that may cause disorders of implantation and
fetus development [5]. Therefore, the study of hemostasis pa-
rameters in pregnant women with thrombophilia is an urgent
scientific problem.
The objective of the research was to study the peculiari-
ties of hemostasis system in pregnant women with fetal loss
syndrome on the background of thrombophilia.
1. Materials and methods
There were examined 90 pregnant women who were divided
into three groups: Group I consisted of 30 pregnant women
with fetal loss syndrome and inborn thrombophilia; Group
II consisted of 30 pregnant women with fetal loss syndrome
and acquired thrombophilia; Group III (the control group) in-
cluded 30 healthy pregnant women without aggravated anam-
nesis.
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The diagnosis of fetal loss syndrome was made based
on the presence of history of three and more spontaneous
miscarriages occurring up to 8 weeks of gestation, and/or at
least one pregnancy loss during the period of more than 8
weeks, including stillbirth (babies born dead after 22 weeks
of gestation or weighting more than 500 grams) and neonatal
death (death of a newborn born after 22 weeks of gestation
or weighting more than 500 grams within 7 days after birth).
Anatomical, genetic, infectious and hormonal reasons of fetal
loss were excluded.
The study of hemostasis system consisted of studying the
procoagulant component, namely the activated recalcification
time (ART), the partial thromboplastin time (PTT), fibrino-
gen levels, the prothrombin index (PTI) according to Quick,
as well as the thrombocytic component, namely the number
of thrombocytes in peripheral blood, and the anticoagulant
component, namely, the activity of antithrombin III (AT III).
The determination of blood thrombophilic status was based
on the detection of thrombophilia marker - D-dimer. The
increase in the concentration of D-dimer by more than 1.0
µg/ml indicated the presence of thrombophilia.
The diagnosis of antiphospholipid syndrome (APS) was
made in case of increased levels of antiphospholipid anti-
bodies (APA) or lupus anticoagulant and fetal loss syndrome.
Laboratory diagnostics of APS was confirmed by APA indices
during blood testing.
The results of the research were statistically processed
using the Student’s t-test.
2. Results and Discussion
The average age of women of Group I was 31.8 ± 6.0 years;
the average age of women of II was 29.6 ± 4.0 years; the
average age of women of Group III was 27.4 ± 4.8 years.
The indices of hemostasis system are presented in Table
1. In pregnant women of all groups, there was observed an
increase in the overall coagulation potential since the first
trimester as evidenced by the increase in the concentration
of the main clot-forming substrate – fibrinogen. Moreover,
during the first trimester, this index in pregnant women with
thrombophilia (Group I – 4.1 ± 0.4 g/l, Group II – 3.9 ± 0.3
g/l) was significantly higher as compared to the indices of the
control group (3.2 ± 0.2 g/l; p<0.05).
During the third trimester and before delivery, there was
observed an increase in fibrinogen levels by 1.5 times (Group
I – 6.2 ± 0.6 g/l, Group II – 5.8 ± 0.4 g/l) as compared to the
results of healthy women (3.8 ± 0.2 g//l; p<0.05).
The level of fibrinogen is one of the most important pa-
rameters characterizing the status of hemostasis system. The
concentration of fibrinogen in the blood plasma changes dra-
matically in different pathological conditions. Fibrinogen is
involved in the final stage of blood sedimentation. The change
in its content in the plasma indicates a disorder of the hemo-
static process, especially in case of disseminated intravascular
coagulation. The degree of hyperfibrinogenemia indicates the
severity of the pathological process. Therefore, the data on the
content of this protein in the blood plasma have a prognostic
value [1].
There was noted an insignificant increase in the PTI in
healthy pregnant women during the third trimester of preg-
nancy (100.6 ± 3.1%) as compared to the indices of the first
and second trimesters (96.1 ± 4.7% and 99.8 ± 2.5%, respec-
tively) which points to the activation of extrinsic coagulation
pathway during delivery [7]. The significant increase in the
PTI was observed in patients with thrombophilia at all the
stages of examination (during the first trimester, the index in
Group I was 98.4 ± 2.6%, in Group II, it was 99.5 ± 3.2%;
during the second trimester, the index in Group I was 101.7
± 3.5%, in Group II, it was 102.3 ± 2.3%; during the third
trimester, the index in Group I was 105.9± 2.6%, in Group II,
it was 106.8 ± 2.2%; p<0.05). Changes in the PTI indicated
the increased activity of extrinsic coagulation pathway factors.
In healthy pregnant women, the obtained indicators were
within the reference range, however, there was a tendency
towards their reduction (during the first trimester, the ART
was 69.1 ± 1.4 seconds, the APTT was 37.2 ± 1.5 seconds;
during the second trimester, the ART was 65.6 ± 1.5 seconds,
the APTT was 36.6 ± 1.9 seconds; during the third trimester,
the ART was 60.1 ± 1.7 seconds, the APTT was 34.3 ± 1.4
seconds). In pregnant women of both Group I and Group II,
there was observed a significant reduction in the aforemen-
tioned parameters (p<0.05) indicating the hypercoagulation
shift being interpreted as a risk factor for thrombosis. The
reduction in the ART index indicated the activation of plasma
and thrombocytic factors of blood coagulation as well.
The indices of platelet count (x109/l) in women of all
groups during pregnancy were within normal range. However,
it should be noted that before delivery there was a tendency
towards their reduction in Group I (209.6 ± 8.3) and II (210.1
± 9.7) while in Group III (243.7 ± 9.6) there was a tendency
towards their increase.
The activation of hemostasis system that leads to the de-
velopment of thrombosis is accompanied by the appearance
of the specific markers in the blood flow which reflect the
degree of increase in hemostatic blood potential. In particular,
the level of D-dimer indicates the intensity of the processes of
thrombogenesis and fibrinolysis. Since the early pregnancy
term, the index of D-dimer increases gradually and the highest
indices are observed in women with complicated course of
pregnancy: preeclampsia, diabetes mellitus, renal diseases etc.
[6].
The average concentration of D-dimer in healthy pregnant
women was 0.5 ± 0.4 µg/ml during the first trimester; during
the second trimester, it was 0.8 ± 0.5 µg/ml; during the
third trimester, it was 1.1 ± 0.1 µg/ml. Pregnancy dynamics
showed a significant increase in the level of D-dimer in groups
of women with thrombophilia as compared to the indices of
healthy pregnant women: during the first trimester, the index
of Group I was 1.2 ± 0.1 µg/ml, in Group II, it was 1.5 ± 0.3
µg/ml; during the second trimester, the index of Group I was
1.6 ± 0.3 µg/ml, in Group II, it was 1.8 ± 0.2 µg/ml; during
Peculiarities of Hemostasis System in Pregnant Women with Fetal Loss Syndrome on the Background of
Thrombophilia — 3/4
Table 1. Indices of hemostasis system during the 1st, 2nd and 3rd trimesters
Group of
women
I II III
n 30 30 30
Index Trimester Trimester Trimester1 2 3 1 2 3 1 2 3
PTI, % 98.4 ±
2.6
101.7 ±
3.5
105.9 ±
2.6
99.5 ±
3.2
102.3 ±
2.3
106.8 ±
2.2
96.1 ±
4.7
99.7 ±
2.5
100.6 ±
3.1
Fibrinogen,
g/l
4.1 ±
0.4*
5.1 ±
0.5*
6.2 ±
0.6*
3.9 ±
0.3*
4.7 ±
0.3*
5.8 ±
0.4*
3.2 ±
0.2
3.6 ±
0.3
3.8 ±
0.2
ART, seconds 63.3 ±
2.1*
62.5 ±
1.8*
51.7 ±
0.8*
62.5 ±
2.1*
60.5 ±
1.7
51.69 ±
1.3*
69.1 ±
1.4
65.6 ±
1.5
60.1 ±
1.7
APTT, sec-
onds
33.6 ±
1.7*
32.9 ±
1.6*
31.4 ±
1.1*
35.1 ±
1.3*
33.2 ±
2.1*
30.7 ±
1.8*
37.2 ±
1.5
36.6 ±
1.9
34.3 ±
1.4
Thrombocytes
(PLT) x109/l
220.3 ±
10.9
218.1 ±
7.6
209.6 ±
8.3*
230.0 ±
10.5
226.5 ±
11.7
210.1 ±
9.7*
232.1 ±
8.3
238.6 ±
5.7
243.7 ±
9.6
D-dimer
(µg/ml)
1.2 ±
0.1*
1.6 ±
0.3*
2.1 ±
0.4*
1.5 ±
0.3*
1.8 ±
0.2*
2.2 ±
0.1*
0.5 ±
0.4
0.8 ±
0,5
1.1 ±
0.1
AT III (%) 86.5 ±
4.8*
84.6 ±
3.5*
82.4 ±
4.7*
87.8 ±
3.2*
82.5 ±
5.7*
81.5 ±
7.7*
110.3 ±
7.8
108.6 ±
9.8
105.3 ±
4.8
Note.
* - statistically significant difference as compared to the control group (p<0.05).
the third trimester, the index of Group I was 2.1 ± 0.4 µg/ml,
in Group II, it was 2.2 ± 0.1 µg/ml, (p<0.05).
In both Group I and Group II, changes in the anticoagu-
lant system were observed as well. Since the first trimester,
there was observed the reduction in AT III activity in patients
with thrombophilia (Group I – 86.5 ± 4.8%, Group II – 87.8
± 3.2%) as compared to the control group (110.3 ± 7.8%,
p<0.05). According to literature data, the reduction in the
level of AT III, in case of systemic inflammation in particular,
is associated with increased consumption of anticoagulation
factors under conditions of coagulation cascade activation, its
destruction under the influence of elastase (the product of ac-
tivated neutrophils), as well as disturbance of its synthesis [7].
During the second trimester, the activity of AT III was 84.6 ±
3.5% in Group I and 82.5 ± 5.7% in Group II, 108.6 ± 9.8%
in the control group, (p<0.05). During the third trimester,
the index of AT III activity was 82.4 ± 4.7% in Group I and
81.5 ± 7.7% in Group II, 105.3 ± 4.8% in the control group
(p<0.05).
3. Conclusions
Thus, in pregnant women with fetal loss syndrome on the
background of thrombophilia, the disorders of the vascular-
platelet and coagulation elements of hemostatic process being
characterized by hypercoagulation, reduction in natural anti-
coagulants (increased levels of fibrinogen, the PTI, decrease
in the ART, the APTT, platelet count, AT III activity), intensi-
fication of thrombosis processes (increased level of D-dimer)
were observed.
4. Prospects for further research
This study gives the possibility to implement the algorithm for
examination of women with a history of fetal loss syndrome
and co-existent thrombophilia thereby preventing thrombophilic
complications during pregnancy.
5. Practical recommendations
Based on the results of the research, we propose to include
dynamic examination of hemostasis system into the algorithm
for management of women with fetal loss syndrome on the
background of thrombophilia since the early terms of preg-
nancy to evaluate thrombophilia activity as well as to predict
pregnancy consequences, to prescribe and evaluate the effec-
tiveness of pathogenetic therapy.
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